Abarceo Pharma
  • About
    • Board Members
  • Team
  • Science
    • Scientific Advisors
  • Pipeline
  • News
  • Contact
Select Page
Almi Invest investerar i Abarceos nya diabetesbehandling

Almi Invest investerar i Abarceos nya diabetesbehandling

by SD-AbarceoPharma | Mar 1, 2021 | Diabetes, News & Press releases

Almi Invest investerar 7,5 miljoner kronor i Abarceo Pharma, som utvecklar ett nytt läkemedel mot diabetes typ 2. I emissionen på totalt 21,5 miljoner kronor deltar även privata investerare. Pengarna ska användas till att nå viktiga milstolpar såsom att välja...

Recent Posts

  • Rapidus: Diabetes companies collect SEK 21.5 million (article in Swedish)
  • Almi Invest investerar i Abarceos nya diabetesbehandling
  • VDAC1 identified as a novel target in Type 2 diabetes

Recent Comments

    Abarceo Pharma AB

    Medeon Science Park
    Per Albin Hanssons vä 41, 205 12
    Malmö, Sweden

    Email: info@abarceo.com

    Abarceo Pharma is a Lund University Holding company and was founded in December 2017 by Scientific founders Prof. Claes Wollheim, MD, and Associate Prof. Albert Salehi. The company is dedicated to developing novel therapeutics for type-2 diabetes based upon a deep molecular and genetic understanding of the disease.

    ©Copyright 2018 – 2022 | All Rights Reserved | Reg. No. 559139-7160 | Privacy Policy